OR WAIT null SECS
Societal CDMO has been awarded a new manufacturing and packaging task order agreement by National Cancer Institute.
Societal CDMO, a contract development and manufacturing organization (CDMO) focused on small-molecule therapeutic development, announced on April 27, 2022 that it has been awarded a new manufacturing and packaging task order agreement by the National Cancer Institute’s Division of Cancer Treatment and Diagnosis (DCTC).
The contract is an individual task order of more than $400,000 to manufacture and package ammonium tetrathiomolibdate (ATTM) capsules. Under the terms of the contract, Societal CDMO will develop and provide DCTD with a scalable manufacturing and packaging process for current good manufacturing practice (CGMP) production of 100 mg ATTM capsules. The project is being funded by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
ATTM acts to interfere with intestinal uptake of copper when administered with meals. It also acts to bind plasma copper when taken between meals. The compound may have the potential to enhance the activity of platinum-based antitumor agents.
“We are pleased to support the NCI and the important research its scientists are undertaking on behalf of cancer patients. By delivering cGMP batches of ATTM to the DCTD, we will be playing an important role in activities designed to advance the battle against cancer, which aligns well with Societal CDMO’s mission and our tagline of ‘Bringing Science to Society,’” said David Enloe, CEO of Societal CDMO, in a press release. “It is validating to be chosen by the NCI to execute this work and we strongly value the trusted relationship we have established with a number of groups within the National Institutes of Health in recent years. We look forward to delivering the high quality process and product that our customers expect from Societal CDMO.”
Source: Recro Pharma